Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

Quantitative autism symptom patterns recapitulate differential
mechanisms of genetic transmission in single and multiple
incidence families
Thomas Frazier
Cleveland Clinic

Eric A. Youngstrom
University of North Carolina at Chapel Hill

Antonio Y. Hardan
Stanford University

Stelios Georgiades
McMaster University

John N. Constantino
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Frazier, Thomas; Youngstrom, Eric A.; Hardan, Antonio Y.; Georgiades, Stelios; Constantino, John N.; and
Eng, Charis, ,"Quantitative autism symptom patterns recapitulate differential mechanisms of genetic
transmission in single and multiple incidence families." Molecular Autism. 6,. 58. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4363

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Thomas Frazier, Eric A. Youngstrom, Antonio Y. Hardan, Stelios Georgiades, John N. Constantino, and
Charis Eng

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/4363

Quantitative autism symptom patterns
recapitulate differential mechanisms of genetic
transmission in single and multiple incidence
families
Frazier et al. Molecular Autism (2015) 6:58
DOI 10.1186/s13229-015-0050-z

Frazier et al. Molecular Autism (2015) 6:58
DOI 10.1186/s13229-015-0050-z

RESEARCH

Open Access

Quantitative autism symptom patterns
recapitulate differential mechanisms of
genetic transmission in single and multiple
incidence families
Thomas W. Frazier1*, Eric A. Youngstrom2, Antonio Y. Hardan3, Stelios Georgiades4, John N. Constantino5
and Charis Eng6

Abstract
Background: Previous studies have demonstrated aggregation of autistic traits in undiagnosed family members
of children with autism spectrum disorder (ASD), which has significant implications for ASD risk in their offspring.
This study capitalizes upon a large, quantitatively characterized clinical-epidemiologic family sample to establish the
extent to which family transmission pattern and sex modulate ASD trait aggregation.
Methods: Data were analyzed from 5515 siblings (2657 non-ASD and 2858 ASD) included in the Interactive Autism
Network. Autism symptom levels were measured using the Social Responsiveness Scale (SRS) and by computing
Diagnostic and Statistical Manual of Mental Disorders—Fifth Edition (DSM-5) symptom scores based on items from
the SRS and Social Communication Questionnaire. Generalized estimating equation models evaluated the influence
of family incidence types (single versus multiple incidence families; male-only ASD-affected families versus families
with female ASD-affected children), diagnostic group (non-ASD children with and without a history of language
delay with autistic speech and ASD-affected children), and sibling sex on ASD symptom levels.
Results: Non-ASD children manifested elevated ASD symptom burden when they were members of multiple
incidence families—this effect was accentuated for male children in female ASD-containing families—or when they
had a history of language delay with autistic qualities of speech. In this sample, ASD-affected children from multiple
incidence families had lower symptom levels than their counterparts in single incidence families. Recurrence risk for
ASD was higher for children from female ASD-containing families than for children from male-only families.
Conclusions: Sex and patterns of family transmission modulate the risk of autism symptom burden in
undiagnosed siblings of ASD-affected children. Identification of these symptoms/traits and their molecular
genetic causes may have significant implications for genetic counseling and for understanding inherited
liabilities that confer risk for ASD in successive generations. Autism symptom elevations were more dramatic
in non-ASD children from multiple incidence families and those with a history of language delay and autistic
qualities of speech, identifying sub-groups at substantially greater transmission risk. Higher symptom burden
and greater recurrence in children from female ASD-containing families indicate that familial aggregation
patterns are further qualified by sex-specific thresholds, supportive of the notion that females require a higher
burden of deleterious liability to cross into categorical ASD diagnosis.
Keywords: Autism spectrum disorder, Multiple incidence families, Genetic epidemiology, Autism symptoms,
DSM-5
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Background
Autism spectrum disorder (ASD) is a phenotypically and
etiologically heterogeneous neurodevelopmental disorder
[1] with common core features of social communication/
interaction impairment and the presence of restricted/repetitive behaviors [2]. Behavioral genetic studies have
identified a strong genetic component [3, 4], derived from
a wide range of genomic mechanisms [5], including possible gene-environment interactions. Family-based studies
of autism symptoms have found evidence of intergenerational transmission via familial aggregation of
elevated scores. At least a subset of unaffected family
members from multiple incidence families, most often siblings and fathers [6], have greater social cognitive [7, 8]
and autism trait burden [9–11], and parents with subtle
elevations of autism traits are at greater risk of having an
ASD-affected child [12].
Recent genetic studies support phenotypic findings,
identifying greater additive genetic burden in multiple
incidence families [13]. However, the exact pattern of
elevated symptom burden in non-ASD children from
single and multiple incidence families remains uncertain.
This leads to several important questions. Do elevated
symptom levels in non-ASD children from multiple incidence families vary across different autism symptom
domains, as would be predicted from studies implying
different etiological influences on social and repetitive
behavior symptoms [14, 15]? Or is a general predisposition observed toward social deficits and restricted/repetitive behavior [3]? Do ASD-affected children from
multiple incidence families also show a more severe
symptom burden relative to their counterparts from single incidence families? Answers to these questions will
provide important information about autism transmission
risk and may provide clues to differences in the mixtures
of etiologic mechanisms between these incidence patterns.
Furthermore, unaffected siblings who have a history of
language delay with autistic qualities of speech (HLDAS)
have greater autism symptom burden [9]. Examining
HLDAS in both single and multiple incidence families is
important for determining whether increased etiologic
burden in unaffected siblings extends beyond multiple
incidence families to a subset of single incidence families
and whether HLDAS further amplifies risk.
Family-based studies can also be helpful for understanding how sex of the affected child influences autism symptom levels. The best known risk factor for autism is being
male [16], and increasingly disparate sex ratios are observed at the higher functioning end of the autism
spectrum [17–19]. An early study focusing on categorical
ASD diagnoses in families did not suggest increased
genetic loading or sex-specific thresholds in families containing ASD-affected females (female ASD-containing
families) [20]. However, more recently, a study of male-
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only and female ASD-containing families found evidence
of higher thresholds for restricted/repetitive behavior in
females [21]. Additionally, using the Autism Genetic
Resource Exchange cohort, Werling and Geschwind identified higher recurrence rates in siblings of female probands [22]. Studies of copy number variation have further
supported the idea of sex-specific thresholds, identifying a
higher mutational burden in ASD-affected females [23]
and differential genetic and hormonal factors that may
contribute to sex-specific thresholds [24]. No previous
studies have investigated whether increased phenotypic
burden in female ASD-containing families extends to both
non-ASD and ASD-affected children, if the pattern differs
across single and multiple incidence families or if autism
symptom measurements yield distinct patterns across
specific Diagnostic and Statistical Manual of Mental
Disorders—Fifth Edition (DSM-5) symptom criteria.
Using the large Interactive Autism Network (IAN) database, the present study investigated these three major factors (single vs. multiple incidence families, HLDAS in
unaffected children, and male-only vs. female ASDcontaining families) to provide a more detailed picture of
genetic burden and transmission risk. Analyses first
focused on autism symptom levels in non-ASD and ASDaffected children from single and multiple incidence families. We anticipated that ASD-affected children from
multiple incidence families would have lower symptom
levels than their counterparts from single incidence families, opposite the pattern of non-ASD children [9], implying a unique etiologic mixture rather than greater overall
symptom and genetic burden. Next, we examined whether
a history of language delay with autistic qualities of speech
in non-ASD siblings resulted in increased symptom burden. We expected that non-ASD children with HLDAS
would show higher symptom levels than non-ASD children without HLDAS and that HLDAS would add to the
enrichment expected for multiple incidence families.
Finally, we evaluated whether the sex of the ASD-affected
child (male-only versus female ASD-containing families)
further modified autism symptom levels. Non-ASD children from female ASD-containing families were predicted
to show higher symptom levels than their counterparts
from male-only families and recurrence risk was expected
to be higher for next-born siblings in female ASDcontaining families.

Methods
Participants

Data were obtained from the IAN (http://www.ianpro
ject.org), an Internet-based registry for families with
one or more ASD-affected children (Data Export ID
IAN_DATA_2013-01-28). Families were eligible for enrollment in IAN if the parent or legal guardian who provided
information was English speaking, the family lived in the
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USA, and their child was diagnosed with ASD by a professional. To be included in the present study, caregivers
must have reported data for at least one ASD-affected
child and at least one additional child. To evaluate symptom levels across child and family characteristics, a subset
of the IAN registry was used with complete data on both
the Social Communication Questionnaire (SCQ) and the
Social Responsiveness Scale (SRS). Previous analyses have
shown that this subset is highly similar to the larger IAN
registry with a few exceptions: the SRS/SCQ subset is
older due to SRS administration beginning at age 4, has
fewer non-verbal individuals likely as a result of several
SRS items tapping the use of language, and has a
greater proportion of white/non-Hispanic youth [25].
Each of these differences was found to be very small in
magnitude (r < .10).
Procedures

Informed consent was obtained from parents/guardians
for all participants prior to entry into the IAN data collection. The procedures of IAN and the present study
were reviewed and approved by the institutional review
boards of Kennedy Krieger Institute and Cleveland
Clinic, respectively.
Demographics, clinical diagnoses, and autism symptoms
were provided by caregivers as part of participation in
IAN. Demographics included: age, sex, and race/ethnicity
(coded as white non-Hispanic and other race/ethnicity).
Each family was coded for two characteristics: (1)
family incidence type and (2) family sex type. To code
families, an index child was first identified by locating
the oldest ASD-affected child associated with each
unique IAN family identifier. Single incidence families
were coded if at least one non-ASD (unaffected) child
and no other ASD-affected children beyond the index
case were associated with the same IAN family identifier. Multiple incidence families were coded if at least
one additional ASD-affected child beyond the index
case was associated with the same IAN family identifier. Female ASD-containing families were coded if at
least one female ASD-affected child and possibly
other male ASD-affected children were present. Maleonly families were coded if all ASD-affected children
in the family were males. Parent and other relative
diagnoses were not consistently available in IAN and
were not considered in family sex-type coding.
Family sex-type definitions followed previous conventions
[21, 22] and, in both types of families, non-ASD female
and male children are possible. Recurrence risk was calculated separately for next-born male and female siblings
and for female ASD-containing and male-only families.
These calculations used the diagnostic classification (ASD
vs. non-ASD) for the oldest available sibling after the
index case in all families [22].
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ASD diagnosis

Caregivers reported whether each registered child was
affected by ASD and, if affected, the specific DSM-IVTR diagnosis obtained from a previous clinical evaluation. In the SRS/SCQ subset of IAN, the vast majority
of clinical ASD diagnoses (93 %) were provided by a
doctoral level professional or team. A substantial proportion of youth (74.9 %) was diagnosed using the Autism
Diagnostic Interview—Revised, the Autism Diagnostic
Observation Schedule, or both. Of these, 98.7 % scored in
the ASD-affected range for one or both instruments.
Recent study of youth from the IAN registry provided
additional support for the validity of clinical ASD diagnoses [26, 27]. Importantly, randomly selected verbal youth
with a score ≥12 on the SCQ were evaluated using the
Autism Diagnostic Interview—Revised and by expert clinician observation. All but a handful of youth (98 %) were
confirmed to have a DSM-IV-TR clinical diagnosis of
ASD. ASD was coded by collapsing all DSM-IV-TR autism
spectrum diagnoses into a single category consistent with
the Center for Disease Control epidemiological catchment
protocols. A substantial minority of the siblings registered
as not having an ASD diagnosis have caregiver-reported
psychiatric or developmental diagnoses (ADHD 12 %, a
history of motor delay 7 %, an anxiety disorder 6 %, mood
disorder 4 %, and intellectual disability 0.5 %). For this reason and to be consistent with previous publications, we
refer to these siblings as non-ASD children [25]. Previous
data have suggested that a subset of unaffected children
from ASD-affected families carry a specific diathesis
toward elevated autism traits [9]. On this basis, non-ASD
children were further divided into those with a history of
language delay and autistic qualities of speech (non-ASD
with HLDAS) and those without (non-ASD) to investigate
whether this distinction identifies children at high risk of
future genetic transmission. HLDAS was coded as positive
if any of SCQ items 3–7 were endorsed consistent with a
previous study [9].

Autism symptoms

Autism symptom constructs were obtained in two ways.
The first used the total and sub-scales of the SRS [28].
The SRS is 65-item, ordinally scaled (1 = “not true” to 4 =
“almost always true”) quantitative assessment of the severity of autism symptoms. The SRS has been extensively
validated and distinguishes youth with autism from other
psychiatric conditions [11, 28]. The present study used
SRS total raw scores to examine family incidence type and
family sex type. In addition to the total score, SRS raw
sub-scale scores were computed as item averages for the
five factor analytically derived scales: emotion recognition,
social avoidance, relationships, repetitive sensory motor,
and insistence on sameness [29].
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DSM-5 symptoms

DSM-5 symptom scores were computed using items
from the SCQ and SRS that were mapped to these criteria [25, 30] (Additional file 1). For each DSM-5 symptom, counts were obtained by summing SCQ and SRS
items mapped to that symptom and then dividing by the
total possible score. This process yielded a single, comparable metric for each of the seven DSM-5 symptoms,
ranging from 0 (no endorsement) to 1 (all items endorsed). Internal consistency reliability was very good
for brief scales (α = .73–.91), indicating that any differences in findings across DSM-5 symptom scales are not
due to differential reliability.
Analytic plan

Independent samples t tests and Pearson’s chi-squared
test were used to compare sample characteristics across
single and multiple incidence families. When non-normal
distributions were observed, non-parametric equivalent
statistics were performed and produced the same pattern
of results. To facilitate effect size comparison, parametric
statistics were reported.
To estimate symptom level differences between single
and multiple incidence families, generalized estimating
equation (GEE) models included individual- and familylevel fixed effects factors: family incidence type (single versus multiple incidence), diagnostic group (ASD versus
non-ASD with and without HLDAS), sex of the child, and
their interactions. Age was also included as a fixed effects
covariate. SRS total raw scores, factor analytically derived
SRS sub-scale scores, and DSM-5 mapped symptom
scores were dependent variables in separate analyses. In
each model, children were clustered within families. The
two-way family incidence type by diagnostic group interaction tested whether autism symptom levels differed
across single and multiple incidence families. The threeway interaction adding sex of the child evaluated whether
this effect differed in male and female children. To explore
whether autism symptom levels were further modified by
male-only families vs. female ASD-containing families, a
similar model was computed to those above except that
family sex type was included as a family-level fixed effects
factor, and models were conducted only for non-ASD siblings. In ASD-affected children, a simpler model was computed with the main effects for family incidence type,
family sex type, and sex of the child due to the fact that
affected females were not present in male-only families.
Independent sample t tests, means, and confidence intervals were used to describe the pattern of results for family
sex type in ASD-affected children. SRS total raw score
was the dependent variable in each analysis.
GEE models were estimated using maximum likelihood,
and fit was considered by iteratively examining alternative
covariance structures and link functions [31]. Final models
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were presented based on unstructured covariance structure and a linear link function, which fit comparably and
yielded a highly similar pattern of results to a Poisson loglinear link function and other covariance structures (e.g.,
independent, autoregressive, and exchangeable). Age and
sex of the child were included in all analyses of SRS raw
scores and DSM-5 symptom scores to ensure these factors
did not confound interpretation of the effect of family
characteristics on autism symptom levels.
To further characterize the meaning of elevated symptom levels in non-ASD children, follow-up analyses
computed Pearson’s correlations estimating bivariate relationships between autism symptoms and developmental milestones: age of independent walking, age of first
meaningful phrase speech, and presence of motor delay.
Additionally, differences in developmental milestones
between non-ASD siblings with and without HLDAS
were computed using analysis of variance for age of
walking and age of first use of meaningful phrase speech
and chi-squared analysis for motor delay.
All analyses were computed in IBM SPSS version 23.
Statistical significance was determined using p < .05.
False discovery rate corrections were applied when multiple autism symptom measures were examined to control for type 1 error inflation due to multiple testing
[32]. Given the large sample size and strong power to
detect small covariate effects (power > .80 for partial
rab.c = .04 and larger), the pattern and magnitude of effects across autism symptom measures were also considered in interpretation. Single degree of freedom F and
X2 statistics were converted to Cohen’s d [33]. Cohen’s d
values ≤.20 and .20–.50 were considered small and
small-to-medium effects, respectively [34].

Results
Sample description

Children from single and multiple incidence families did
not significantly differ on age, race/ethnicity, or the presence of DSM-IV-TR diagnoses of autistic disorder or
pervasive developmental disorder not otherwise specified
(Table 1). Interestingly, multiple incidence families had a
higher proportion of ASD-affected children who received a diagnosis of Asperger’s disorder (21.0 %) relative
to single incidence families (15.4 %).
Single versus multiple incidence families

Reliable differences in autism symptom levels were seen
between children from single and multiple incidence families (Table 2; smallest p = .009 for DSM-5 B2: resistance
to change) with all measures surviving false discovery rate
correction. The only exception was DSM-5 A2: nonverbal communication where only a trend was observed
(p = .051). Additional file 2 presents the full analytic
results for SRS total raw scores.
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Table 1 Sample characteristics of children with autism symptom questionnaire data from single and multiple incidence families in IAN
Single incidence families

Multiple incidence families

2262

315

Female ASD-containing (N, %)

334 (14.8 %)a

125 (39.7 %)b

Male-only (N, %)

1928 (85.2 %)a

190 (60.3 %)b

Number of families

Number of children

Χ2, t(p)
Χ2(1) = 117.3 (p < .001)

4764

751

ASD (N, %)

2262 (48.8 %)a

596 (80.6 %)b

Non-ASD (N, %)

2097 (45.2 %)a

121 (16.4 %)b

Non-ASD with HLDAS

280 (6.0 %)a

22 (3.0 %)b

Age (M, SD, range)

8.7 (3.8, 4–18)

8.8 (3.6, 4–18)

Female siblings (N, %)

1602

221

ASD (N, %)

333 (20.8 %)a

141 (63.8 %)b

Non-ASD with HLDAS (N, %)

118 (7.4 %)

11 (5.0 %)

Non-ASD (N, %)

1151 (71.8 %)a

69 (31.2 %)b

White non-Hispanic

4248 (89.2 %)

684 (91.1 %)

Other or unknown

516 (10.8 %)

67 (8.9 %)

SCQ total raw (M, SD)

12.4 (11.4)

17.5 (10.3)

t(5513) = −11.54 (p < .001)

SRS total T score (M, SD)

64.7 (23.8)

77.1 (21.2)

t(5513) = −13.47 (p < .001)

Autistic disorder

950 (42.0 %)

239 (40.1 %)

Χ2(2) = 10.7 (p = .005)

PDD NOS

963 (42.6 %)

232 (38.9 %)

Asperger’s disorder

349 (15.4 %)a

125 (21.0 %)b

Χ2(2) = 261.1 (p < .001)

t(5513) = −0.6 (p = .522)
Χ2(2) = 187.7 (p < .001)

Race/ethnicity
Χ2(1) = 2.5 (p = .114)

DSM-IV-TR (N, %)

N = 137 non-ASD siblings could not be coded into HLDAS due to the missing data regarding the presence of language delay. The numbers of children in each category
represent the number of children with complete symptom data and not the total number of children in the family. The numbers for DSM-IV-TR reflect only those with a
specific DSM-IV-TR reported diagnosis. A small proportion of ASD-affected individuals did not have a specific DSM-IV-TR diagnosis reported (ASD or PDD was
listed instead of a specific diagnosis). Lowercase letters a and b represent column proportions that are significantly different (Bonferroni adjusted p < .05).
Age is presented as the child’s age when the SRS was completed

Non-ASD children without HLDAS from multiple incidence families had higher levels of autism symptoms
on the SRS relative to non-ASD children without
HLDAS from single incidence families (Fig. 1). This pattern was also generally true for DSM-5 symptoms but
the size and significance of effects was variable; significant differences were only observed for DSM-5 B2: resistance to change and B3: restricted interests (Fig. 2).
Conversely, ASD-affected children from single incidence
families had significantly higher autism symptoms (Fig. 1)
than ASD-affected children from multiple incidence
families. The effect was largest for B1: repetitive motor
(Fig. 2). Inspection of scores indicates that effects were
small, but not trivial, with SRS total raw score differences of 4–8 points between children from single and
multiple incidence families. As a result, frequency distributions of SRS total raw scores were farther apart in
non-ASD and ASD-affected children from single incidence families and closer together in multiple incidence
families (Additional file 3 presents the SRS total raw
score distributions). Females from multiple incidence
families show a distinctly bimodal distribution, replicating

previous findings regarding sex-specific aggregation patterns in multiple incidence families [35].
In all non-ASD children, higher autism symptom level
was significantly and positively related to age of walking
independently, age of first meaningful phrase speech,
and the presence of a motor delay (r = .06–.21, p < .002),
supporting the developmental relevance of observed
symptom elevations.
Non-ASD children with HLDAS

Non-ASD children with HLDAS had higher levels of
autism symptoms on the SRS (Fig. 1) and higher
levels of DSM-5 symptoms (Table 2) relative to nonASD children without HLDAS (all p values <.001).
These effects were generally medium to large in magnitude (Cohen’s d = .25–.84). Non-ASD children with
HLDAS also showed significant delays in developmental milestones relative to non-ASD children without
HLDAS, including walking independently (14.4 vs.
12.0 months; F(1,2361) = 48.45, p < .001), age of first
meaningful phrase speech (21.0 vs. 14.5 months;
F(1,2414) = 85.19, p < .001), and the presence of a
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Table 2 Autism symptom levels in non-ASD, non-ASD with HLDAS, and ASD-affected children by family incidence type
Non-ASD siblings

Non-ASD siblings with HLDAS

ASD siblings

Family incidence
type by diagnostic
group

Single
incidence
families

Multiple
incidence
families

Single
incidence
families

Multiple
incidence
families

Single
incidence
families

Multiple
incidence
families

M (SD)

M (SD)

M (SD)

M (SD)

M (SD)

M (SD)

Total raw score

19.7 (19.4)

27.9 (27.3)

41.4 (31.4)

45.5 (25.6)

105.6 (29.0)

101.0 (33.1)

17.28 (<.001)

Emotion recognition

.41 (.37)

.56 (.52)

.83 (.56)

.87 (.44)

1.85 (.48)

1.79 (.55)

14.45 (.001)

Social avoidance

.19 (.31)

.27 (.42)

.35 (.45)

.45 (.51)

1.16 (.62)

1.08 (.65)

9.28 (.010)

Interpersonal relationships

.23 (.39)

.38 (.55)

.57 (.67)

.72 (.71)

1.69 (.66)

1.59 (.71)

11.26 (.004)

Repetitive sensory motor

.19 (.26)

.25 (.31)

.45 (.45)

.48 (.36)

1.35 (.60)

1.26 (.65)

18.11 (<.001)

Insistence on sameness

.29 (.33)

.42 (.46)

.60 (.52)

.66 (.45)

1.63 (.51)

1.56 (.55)

16.75 (<.001)

A1: socio-emotional reciprocity

.08 (.12)

.12 (.14)

.19 (.20)

.19 (.16)

.61 (.21)

.59 (.24)

14.20 (.001)

A2: non-verbal communication

.15 (.14)

.16 (.15)

.27 (.19)

.29 (.16)

.64 (.19)

.61 (.21)

5.97 (.051)

A3: relationships

.07 (.14)

.11 (.18)

.20 (.24)

.23 (.23)

.68 (.24)

.63 (.27)

11.80 (.003)

Χ2 (p)

SRS

DSM-5 SCI

DSM-5 RRB
B1: repetitive motor

.03 (.10)

.05 (.13)

.09 (.18)

.08 (.18)

.60 (.30)

.53 (.32)

21.74 (<.001)

B2: resistance to change

.13 (.17)

.19 (.24)

.26 (.23)

.30 (.22)

.65 (.24)

.64 (.24)

9.43 (.009)

B3: restricted interests

.06 (.14)

.11 (.16)

.17 (.22)

.17 (.19)

.66 (.25)

.62 (.27)

18.96 (<.001)

B4: abnormal sensory

.05 (.11)

.08 (.13)

.15 (.21)

.12 (.16)

.53 (.25)

.49 (.27)

17.96 (<.001)

Higher raw and T scores indicate higher levels of autism traits. Factor analytically derived SRS sub-scales are presented as raw item averages (range 0–3; 0 = not
true, 1 = sometimes true, 2 = often true, 3 = almost always true). T scores are not currently available for these sub-scales. Each DSM-5 symptom score represents
the proportion of endorsed items mapped to that symptom. Scale endpoints represent: 0 = no items endorsed by any individual and 1 = all items endorsed
across all individuals

motor delay (25.8 vs. 3.1 %; X2(1) = 252.18, p < .001).
Non-ASD children with HLDAS from multiple incidence families had only slightly higher autism symptom levels relative to non-ASD children with HLDAS
from single incidence families, suggesting HLDAS and
family type do not result in additive increases in risk
of genetic transmission.
Male-only versus female ASD-containing families

Lumping non-ASD male and female siblings together,
there was no increase in autism symptom burden in
female ASD-containing versus male-only families
(X2(1) = 0.60, p = .439; Additional file 4). However,
non-ASD males from multiple incidence female ASDcontaining families had significantly elevated autism
symptom levels relative to other non-ASD children
(≥11 SRS total raw score points higher) (X2(1) = 6.74,
p = .009; Fig. 3a; Additional file 5 presents the full
analytic results in non-ASD children). All post hoc
comparisons between non-ASD males from multiple
incidence female ASD-containing families were significant (p ≤ .037), with the exception of only a weak
trend for non-ASD female children from multiple incidence male-only families (p = .295).

ASD-affected children from female ASD-containing
families had significantly higher autism symptom levels
than ASD-affected children from male-only families
(Additional file 6). Inspection of means and confidence
intervals suggests that this effect was driven by higher
autism symptom levels in ASD-affected males from multiple incidence female ASD-containing families relative
to other ASD-affected children from multiple incidence
families (≥8 SRS total raw score points higher) (smallest
t(453) = 2.16, p = .031; Fig. 3b). ASD-affected males and
females from single incidence families had comparable
symptom levels.
Congruent with well-documented sex rations in ASD,
recurrence risk was significantly higher for next-born
males (22.0 %) than next-born females (8.6 %) (RR = 2.56,
95 % confidence interval (CI) = 2.15–3.07). More interestingly, recurrence of ASD in female ASD-containing
families (31.6 %) was nearly three times higher than in
male-only families (11.9 %) (RR = 2.66, 95 % CI = 2.29–
3.09) (Additional file 7).

Discussion
The present study replicated a growing literature showing greater autism symptom burden in non-ASD family
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Fig. 1 Autism symptoms (M +/− 95 % CI) in non-ASD, non-ASD with HLDAS, and ASD-affected children from single and multiple incidence families.
HLDAS History of language delay with autistic speech

members from multiple incidence families [7–9, 12,
36, 37] and generated four unique findings not previously described. First, non-ASD children from multiple incidence families had a specific pattern of
increased DSM-5 symptom burden. In these children,
symptom increases were strongest for behaviors that
are prominent in cognitively able individuals with autism (B2: resistance to change, B3: restricted interests).
This pattern cannot be explained by differential reliability of scores and instead may indicate that B2 and
B3 symptoms are more sensitive to broad ASD-like
phenotypic presentations. The pattern may also imply
the presence of increased burden of inherited liabilities in multiple incidence families, such as common
variation in genes important for the functioning of

cortico-striatal-thalamic circuits influencing the manifestation of repetitive/perseverative behavior. In contrast to non-ASD children, ASD-affected children
from single incidence families showed increased levels
of DSM-5 repetitive motor symptoms associated with
cognitively impaired presentations of ASD. This may
indicate a disproportionate representation of severely
affected individuals in single incidence families, possibly due to strong, de novo genetic variants (large
copy number variations (CNVs), multiple deleterious
variants) modifying basic aspects of brain development. The lack of elevated autism symptoms in the
majority of non-ASD children from single incidence
families, particularly those without HLDAS, further
supports the possibility that de novo events or rare

Fig. 2 Effect sizes (Cohen’s d) representing differences between single and multiple incidence families across DSM-5 symptom domains, separately for
ASD and non-ASD children. *p < .05; **p < .01. Positive effect sizes represent higher symptom levels in youth from single incidence families (orange
bars). Negative effect sizes represent higher symptom levels in youth from multiple incidence families (light blue bars)
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Fig. 3 Autism symptom levels (M +/− 95 % CI) in female ASD-containing and male-only families, separately for non-ASD (left panel) and ASD-affected
children (right panel)

recessive mutations of large effect may be driving autism in a significant proportion of single incidence
families [11, 38].
The second novel finding was that ASD-affected children from multiple incidence families show the opposite
pattern of their non-ASD sibling counterparts—decreased
symptom burden. Thus, in multiple incidence families,
non-ASD and ASD-affected children have closer levels of
autism severity, whereas a wider spread of severity is seen
in single incidence families. This pattern supports the
presence of unique etiologic mixtures in single and multiple incidence families, although the exact nature of the
differences in etiologic mixture cannot be discerned from
symptom data. A recent study of common variants identified a stronger contribution of additive genetic variation
in multiple incidence families [13], while studies of de
novo CNVs have suggested enrichment in single incidence
families [39, 40]. Subtle differences in the prevalence of
common variants of small effect and de novo rare variants
of large effect may be leading to small, but meaningful,
differences in symptom aggregation between single and
multiple incidence families. The present results highlight
the importance of accounting for family incidence type in
future etiologic investigations.
Third, HLDAS appears to be a major risk factor for
elevated, but still sub-threshold, autism symptom levels
[9]. Non-ASD children with HLDAS had substantially
higher levels of autism symptoms (Δ18–21 SRS total raw
score points) relative to non-ASD children without
HLDAS, and elevations were present across both social
and restricted/repetitive behavior domains. Given this
pattern, non-ASD children with HLDAS, including those
from single incidence families, may be at substantially
greater risk of genetic transmission of autism. Prospective studies are needed to confirm this observation,
examine rates of fecundity in these individuals, and estimate the risk of ASD in their offspring.

The final novel finding has increased autism symptom
burden in next-born male siblings from multiple incidence female ASD-containing families and greater recurrence risk for all siblings in female ASD-containing
families. This finding is congruent with Szatmari and
colleagues [21] and the sex-specific threshold model.
Under this model, females may require additional disease burden to cross threshold [23, 41, 42], with some
females remaining sub-threshold [43] and possibly meeting DSM-5 criteria for social communication disorder or
other developmental psychiatry disorders rather than
autism spectrum disorder. It is important to note that
previous studies lumping male and female non-ASD siblings from female ASD-containing families found a general increase in autism symptom burden. In the present
study, the increase in symptom burden in siblings from
female ASD-containing families was attenuated and
non-significant when male and female non-ASD siblings
were lumped. It is possible that previous significant findings using a lumped sibling group may have been driven
by a larger increase in male non-ASD siblings. Alternatively, the present results may represent a false negative
due to sampling variation in female non-ASD siblings.
Regardless, the present findings raise the interesting possibility that all children from female ASD-containing
families may be at higher recurrence risk, but residual
symptom burden may be most apparent in non-ASD
males from female ASD-containing families. If true,
non-ASD females may be less likely than non-ASD
males to exhibit the increase in risk behaviorally because
of the presence of female-specific protective factors (e.g.,
social, hormonal, or genetic factors). Use of blinded,
clinician-rated, quantitative instruments will be essential
for clarifying the true pattern, ruling out the possibility
of rater biases, and determining the exact nature of
transmission of symptom elevations in pedigrees from
female ASD-containing families.
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Limitations and future directions

The primary limitations of the present study were reliance on caregiver-reported symptoms and the use of
data from an Internet-based registry. The IAN registry is
carefully maintained with ease of reporting for parents.
However, it is possible that some caregivers did not report data for an unaffected sibling. Many families in the
registry contain multiple unaffected children and, if
present, the most likely impact of under-reporting unaffected children is to reduce power to detect differences.
Caregiver-reported symptoms are susceptible to rater
biases. For example, it is possible that the rater contrast
between ASD-affected and non-ASD children in single
incidence families is stronger and therefore leads caregivers to generate polarized ratings. However, this possibility seems unlikely to account for the observed pattern
because: (1) the full range of symptom levels was observed in both single and multiple incidence families, (2)
DSM-5 symptom increases in non-ASD children was
stronger to symptom presentations seem more frequently in cognitively able individuals (B2: resistance to
change and B3: restricted interests) rather than being a
general increase across all symptoms and could not be
accounted for by differential reliability, and (3) recurrence risks for categorical ASD diagnosis were consistent
with symptom level findings. Rater contrast effects could
also work in the opposite direction by reducing power
and leading to underestimation of symptom level increases in non-ASD siblings from multiple incidence
families. Thus, on balance, it seems unlikely that rater
contrast effects generated the overall pattern of findings.
Future studies that include clinician-rated symptoms,
teacher-report data [11], or objective measurements of
cognitive processes associated with the broad autism
phenotype [7] will be helpful for further uncovering relationships between family structure or pedigree and
phenotypic presentation.
Mapping of SRS and SCQ items to DSM-5 symptoms
is a proxy for actual DSM-5 symptom ratings obtained
as part of a comprehensive diagnostic evaluation. Future
studies using DSM-5 symptom ratings will be essential
to confirm the interesting pattern of symptom elevations
in multiple incidence families. An additional limitation is
that the IAN Internet registry is not representative of all
families affected by ASD, due to over-inclusion of white
non-Hispanic children and high socioeconomic status
families, and does not include data from families unaffected by ASD. The presence of data from youth
whose families are not affected by ASD might assist in
interpreting the pattern of findings for non-ASD children from single and multiple incidence families. In spite
of these limitations, the national scope and large size of
the IAN registry—as well as the simultaneous collection
of single and multiple incidence families—make it
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powerful for quantifying the effects of family structure
on autism while covering the full range of autism symptom severity.
It is important to consider that the magnitude of family incidence and family sex effects in this study tended
to be small in size. Effect sizes representing differences
between single and multiple incidence families may be
reduced due to stoppage—a decision to curtail future
reproduction [44], without which a proportion of single
incidence families would be re-classified as multiple incidence families. However, pedigree transmission studies
identifying powerful genetic effects transmitted from unaffected mothers imply similar genetic mechanisms in at
least a subset of single and multiple incidence families
[45, 46]. Clearly, additional etiologic investigations are
needed to sort out these mixtures, but the present results identifying relatively modest symptom differences
suggests that etiologic mechanisms may differ in proportion but not in kind [39].

Conclusions
With these limitations considered, the present findings
replicated previous data identifying elevated autism
symptoms in non-ASD children from multiple incidence
families and extended these findings by showing the opposite pattern in ASD-affected children. Aggregation of
autism symptoms was also influenced by the presence of
the HLDAS phenotype in non-ASD youth and in families
with an ASD-affected female, both of which increased
burden. Non-ASD youth from multiple incidence families
and youth with HLDAS appear to be at substantially elevated risk of autism transmission to their offspring.
Finally, elevated symptom levels and recurrence risk in
female ASD-containing families support the notion of
sex-specific thresholds where females require greater genetic loading to meet ASD diagnostic criteria. Future largescale studies that carefully ascertain family pedigrees and
code for additional aspects of family structure (e.g., broad
phenotype in biological parents) and include blinded
clinician-rated and objective measures are needed to further clarify the genetic epidemiology of autism. These
studies will be necessary for tailoring genetic counseling
and for understanding background inherited liabilities that
confer risk for clinical ASD in successive generations.
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Additional file 1: Social Communication Questionnaire (SCQ) and
Social Responsiveness Scale (SRS) item mapping to DSM-5 criteria.
This file provides the SCQ and SRS items which map to each of the DSM-5
criteria to create DSM symptom scores.
Additional file 2: Main effect and interaction tests examining SRS
total raw score by family incidence type and diagnostic status. This
file provides generalized estimating equation results for main effects and
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interactions examining autism symptom levels across single and multiple
incidence families.
Additional file 3: Frequency distributions of SRS total raw scores
in non-ASD and ASD-affected children from single and multiple
incidence families, separately for female and male children. This
file provides frequency distributions for SRS total raw scores by family
incidence type and sex of the child.
Additional file 4: Autism symptom levels (M + 95 % CI) in non-ASD
siblings (male and female siblings combined) from female
ASD-containing and male-only families, separately for single
and multiple incidence families. This file provides SRS total raw
scores (M +/−95 % CI) in all non-ASD children by family incidence type
and family sex type.
Additional file 5: Main effect and interaction tests examining SRS
total raw score by family incidence type and family sex type in
non-ASD siblings. This file provides generalized estimating equation
results for autism symptom levels across family incidence type and family
sex type in non-ASD children.
Additional file 6: Main effects examining SRS total raw score by
family incidence type and family sex type in ASD-affected siblings.
This file provides generalized estimating equation results for autism
symptom levels by family incidence type and family sex type in
ASD-affected children.
Additional file 7: Recurrence risk of ASD in next-born siblings by
sex of the sibling and family sex type. This file provides recurrence risk
estimates for next-born siblings separately for male and female siblings
and for male-only and female ASD-containing families.
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